Tempus AI, Inc.
Business
Tempus AI, Inc. develops AI-driven Intelligent Diagnostics that connect laboratory results to patients’ clinical, molecular, and imaging data to personalize diagnostic insights and guide therapy selection. It offers Genomics testing (NGS, PCR, transcriptomic and methylation assays, liquid and tissue biopsies, hereditary screening), Data and Services (licensed de-identified multimodal datasets, analytics, clinical trial matching and organoid modeling), and AI Applications (algorithmic diagnostics and clinical decision support such as the Next platform and various Algos). Tempus operates a vertically integrated platform with proprietary software, laboratories, and data pipelines, and distributes services primarily through clinician ordering, provider integrations, and life sciences partnerships across the United States and select international collaborations.
Summary from filing dated 2025-02-24
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Total net revenue | 1,272 | 693 | 532 | 321 | |
| Technology research and development | 146 | 168 | 95 | 79 | |
| Research and development | 173 | 149 | 90 | 83 | |
| Selling, general and administrative | 732 | 755 | 297 | 233 | |
| Total cost and operating expenses | 1,525 | 1,384 | 728 | 586 | |
| Loss from operations | −253 | −691 | −196 | −265 | |
| Interest income | 13 | 11 | 8 | 3 | |
| Interest expense | −70 | −54 | −47 | −22 | |
| Loss on debt extinguishment | −12 | 0 | 0 | — | |
| Other income, net | 31 | 32 | 22 | −5 | |
| Loss before benefit from (provision for) income taxes | −291 | −701 | −214 | −289 | |
| benefit from (Provision for) income taxes | 52 | −266,000 | −288,000 | — | |
| losses from equity method investments | −6 | −4 | −301,000 | −595,000 | |
| Net Loss | −245 | −706 | −214 | −290 | |
| Accretion of convertible preferred stock to redemption value | 0 | 0 | −4 | −301,000 | |
| Dividends on Series A, B, B-1, B-2, C, D, E, F, G, G-3, and G-4 preferred shares | 0 | −39 | −44 | −41 | |
| Cumulative undeclared dividends on Series C preferred shares | 0 | −1 | −3 | −3 | |
| Net loss attributable to common shareholders, basic | −245 | −746 | −266 | −334 | |
| Net loss attributable to common shareholders, diluted | −245 | −746 | −266 | −334 | |
| Net loss per share attributable to common shareholders, basic | −1.41 | −6.23 | −4.2 | −5.3 | |
| Net loss per share attributable to common shareholders, diluted | −1.41 | −6.23 | −4.2 | −5.3 | |
| Weighted-average shares outstanding used to compute net loss per share, basic | 174,264 | 119,849 | 63,306 | 63,306 | |
| Weighted-average shares outstanding used to compute net loss per share, diluted | 174,264 | 119,849 | 63,306 | 63,032 | |
| Foreign currency translation adjustment | 808,000 | 89,000 | −13,000 | 29,000 | |
| Comprehensive loss | −244 | −706 | −214 | −290 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 605 | 341 | 166 | 303 | — | |
| Accounts receivable, net of allowances of $2,755 and $1,141 at December 31, 2025 and 2024, respectively | 311 | 155 | 94 | — | — | |
| Inventory | 52 | 38 | 29 | — | — | |
| Related party asset | 9 | — | — | — | — | |
| Prepaid expenses and other current assets | 40 | 26 | 17 | — | — | |
| Marketable equity securities | 150 | 107 | 32 | — | — | |
| Total current assets | 1,167 | 668 | 350 | — | — | |
| Property and equipment, net | 89 | 58 | 62 | — | — | |
| Goodwill | 470 | 73 | 73 | 53 | — | |
| Intangible assets, net | 355 | 12 | 22 | — | — | |
| Investments and other assets | 21 | 8 | 9 | — | — | |
| Investment in joint venture | 87 | 91 | 0 | — | — | |
| Related party asset, less current portion | 16 | — | — | — | — | |
| Operating lease right-of-use assets | 64 | 15 | 21 | — | — | |
| Restricted cash | 5 | 900,000 | 800,000 | — | — | |
| Total Assets | 2,275 | 926 | 564 | — | — | |
| Accounts payable | 82 | 54 | 54 | — | — | |
| Accrued expenses | 155 | 130 | 83 | — | — | |
| Deferred revenue | 93 | 76 | 65 | — | — | |
| Deferred other income | 16 | 16 | 0 | — | — | |
| Other current liabilities | 9 | 7 | 8 | — | — | |
| Operating lease liabilities | 13 | 6 | 6 | — | — | |
| Accrued data licensing fees | 4 | 2 | 6 | — | — | |
| Total current liabilities | 372 | 291 | 233 | — | — | |
| Operating lease liabilities, less current portion | 74 | 26 | 32 | — | — | |
| Convertible promissory note | 209 | 168 | 193 | — | — | |
| Other long-term liabilities | 57 | 16 | 20 | — | — | |
| Revolving credit facility | 100 | — | — | — | — | |
| Interest payable | 12 | 70 | 55 | — | — | |
| Long-term debt, net | 203 | 267 | 257 | — | — | |
| Convertible senior notes, net | 728 | — | — | — | — | |
| Deferred other income, less current portion | 8 | 24 | 0 | — | — | |
| Deferred revenue, less current portion | 20 | 7 | 17 | — | — | |
| Total Liabilities | 1,784 | 870 | 841 | — | — | |
| Commitments and contingencies | — | — | — | — | — | |
| Convertible redeemable preferred stock, $0.0001 par value, 20,000,000 shares authorized at December 31, 2025 and 2024, respectively, no shares issued and outstanding at December 31, 2025 and 2024 | 0 | 0 | 1,106 | — | — | |
| Treasury Stock, 183,229 and 145,466 shares at December 31, 2025 and 2024, respectively, at cost | −7 | −4 | −4 | — | — | |
| Additional Paid-In Capital | 2,893 | 2,211 | 18 | — | — | |
| Accumulated Other Comprehensive Income | 902,000 | 94,000 | 5,000 | — | — | |
| Accumulated deficit | −2,396 | −2,151 | −1,397 | — | — | |
| Total Stockholders' equity | 491 | 56 | −1,382 | −1,129 | −807 | |
| Total Liabilities, Convertible redeemable preferred stock, and Stockholders' equity | 2,275 | 926 | 564 | — | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Change in fair value of warrant liability | 0 | 42 | −8 | 5 | |
| Gain on warrant termination | 0 | −39 | 0 | 0 | |
| Reversal of warrant contract asset amortization | 0 | −16 | 0 | 0 | |
| Stock-based compensation | 125 | 534 | 0 | 0 | |
| Gain on warrant exercise | 0 | −173,000 | 0 | 0 | |
| Gain on marketable equity securities | −16 | −12 | −10 | 0 | |
| Loss on disposal of property and equipment | 415,000 | 0 | 0 | — | |
| Deferred income taxes | −53 | 0 | 0 | — | |
| Amortization of original issue discount | 4 | 1 | 1 | 238,000 | |
| Amortization of deferred financing fees | 484,000 | 510,000 | 510,000 | 139,000 | |
| Change in fair value of contingent consideration | 0 | 72,000 | −400,000 | −4 | |
| Change in fair value of holdback liability | −1 | 0 | 0 | — | |
| Amortization of warrant contract asset | 0 | 5 | 5 | 5 | |
| Depreciation and amortization | 102 | 37 | 33 | 30 | |
| Provision for bad debt expense | 3 | 680,000 | 2 | 4 | |
| Provision for obsolete inventory | 1 | 0 | 0 | 2 | |
| Amortization of finance right-of-use lease assets | 0 | 0 | 283,000 | 381,000 | |
| Change in fair value of warrant asset | 0 | −18 | −4 | 0 | |
| Non-cash operating lease costs | 12 | 6 | 7 | 6 | |
| Minimum accretion expense | 268,000 | 197,000 | 90,000 | 455,000 | |
| Impairment of intangible assets | 0 | 0 | 7 | 0 | |
| PIK interest added to principal | 11 | 9 | 4 | 0 | |
| Accounts receivable | −90 | −61 | −7 | −8 | |
| Inventory | −3 | −10 | −7 | −1 | |
| Prepaid expenses and other current assets | −2 | −14 | −6 | −1 | |
| Investments and other assets | −17 | −751,000 | −4 | −2 | |
| Accounts payable | −7 | −24 | −23 | −8 | |
| Related party asset | −25 | 0 | 0 | — | |
| Deferred revenue | −7 | −21 | −26 | 68 | |
| Deferred other income | −16 | 40 | 0 | 0 | |
| Accrued data licensing fees | 3 | −5 | −9 | −7 | |
| Accrued expenses & other | −13 | 51 | 39 | 23 | |
| Interest payable | 14 | 15 | 16 | 16 | |
| Operating lease liabilities | −15 | −9 | −9 | −7 | |
| Net cash used in operating activities | −218 | −189 | −214 | −168 | |
| Purchases of property and equipment | −21 | −22 | −35 | −18 | |
| Proceeds from sale of marketable equity securities | 8 | 23 | 0 | 0 | |
| Purchases of marketable equity securities | −3 | −36 | 0 | 0 | |
| Business combinations, net of cash acquired | −377 | 0 | −6 | −40 | |
| Investment in joint venture | 0 | −95 | 0 | 0 | |
| Capitalized software costs | −6 | 0 | 0 | — | |
| Net cash used in investing activities | −398 | −130 | −40 | −58 | |
| Proceeds from issuance of common stock in connection with initial public offering, net of underwriting discounts and commissions | 0 | 382 | 0 | 0 | |
| Tax withholding related to net share settlement of restricted stock units | 0 | −70 | 0 | 0 | |
| Issuance of Series G-4 Preferred Stock, net of offering costs | 0 | 0 | 45 | — | |
| Issuance of Series G-5 Preferred Stock | 0 | 200 | 0 | 0 | |
| Principal payments on finance lease liabilities | 0 | 0 | −288,000 | −375,000 | |
| Purchase of treasury stock | −3 | 0 | −4 | 0 | |
| Payment of deferred offering costs | −806,000 | −9 | −698,000 | −3 | |
| Dividends paid | 0 | −6 | −6 | −6 | |
| Proceeds from revolving credit facility, net of original issue discount | 98 | 0 | 0 | — | |
| Proceeds from long-term debt, net of original issue discount | 196 | 0 | 83 | 171 | |
| Proceeds from convertible senior notes, net of initial purchasers' discount | 726 | 0 | 0 | — | |
| Payment of deferred financing fees | −2 | 0 | 0 | −3 | |
| Payment of indemnity holdback related to acquisition | 0 | −813,000 | 0 | 0 | |
| G-4 Special Payment | 0 | −2 | 0 | 0 | |
| Principal payments on long-term debt | −277 | 0 | 0 | — | |
| Prepayment premium on long-term debt | −8 | 0 | 0 | — | |
| Purchases of capped call | −42 | 0 | 0 | — | |
| Proceeds from issuance of common stock in connection with at-the-market offering, net of commissions | 195 | 0 | 0 | — | |
| Net cash provided by financing activities | 884 | 494 | 118 | 251 | |
| Effect of foreign exchange rates on cash | −62,000 | 336,000 | −19,000 | 17,000 | |
| Net increase (decrease) in Cash, Cash Equivalents and Restricted Cash | 268 | 175 | −137 | 25 | |
| Cash paid during the year for interest | 44 | 28 | 17 | 5 | |
| Cash paid for income taxes | 654,000 | 206,000 | 161,000 | 6,000 | |
| Marketable equity securities received on accounts receivable | 32 | 22 | 22 | 0 | |
| Dividends Payable | 0 | 5 | 13 | 6 | |
| Purchases of property and equipment, accrued but not paid | 6 | 4 | 6 | 2 | |
| Redemption of convertible promissory note | 32 | 25 | 28 | 17 | |
| Non-voting common stock issued in connection with business combinations | 0 | 344,000 | 9 | 5 | |
| Accretion of convertible preferred stock to redemption value | 0 | 0 | 4 | 301,000 | |
| Deferred offering costs, accrued but not yet paid | 47,000 | 0 | 4 | 2 | |
| Deferred financing fees, accrued but not yet paid | 226,000 | 0 | 0 | — | |
| Reclassification of deferred offering costs to additional paid-in capital upon at-the-market offering | 821,000 | 0 | 0 | — | |
| Operating lease liabilities arising from obtaining right-of-use assets | 23 | 2 | 1 | 42 | |
| Conversion of redeemable convertible preferred stock to common stock in connection with initial public offering | 0 | 1,349 | 0 | 0 | |
| Taxes related to net share settlement of restricted stock units not yet paid | 0 | 20,000 | 0 | 0 | |
| Reclassification of deferred offering costs to additional paid-in capital upon initial public offering | 0 | 12 | 0 | 0 | |
| Class A Common Stock issued in connection with business combinations | 403 | 0 | 0 | — | |
| Class A Common Stock issued in connection with license agreement | 1 | 0 | 0 | — | |
| Issuance of warrant | 0 | 0 | 4 | 0 | |
| Issuance of common stock in connection with contingent consideration | 0 | 847,000 | 0 | 0 | |
| Convertible promissory note principal reset due to amendment | 72 | 0 | 0 | — |